يعرض 1 - 10 نتائج من 159 نتيجة بحث عن '"Ryu M.-H."', وقت الاستعلام: 1.17s تنقيح النتائج
  1. 1
    دورية أكاديمية
    Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody–drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study

    المؤلفون: Gazzah, A., Bedard, Philippe L., Hierro Carbó, Cinta, Kang, Yoon-Koo, Abdul Razak, A., Ryu, M.-H., Tabernero Caturla, Josep

    المساهمون: Institut Català de la Salut, Gazzah A Drug Development Department, Gustave Roussy, Villejuif Cedex, Villejuif, France. Bedard PL, Abdul Razak A Division of Medical Oncology & Hematology, Department of Medicine, Princess Margaret Cancer Centre–University Health Network, University of Toronto, Toronto, Canada. Hierro C Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Kang YK, Ryu MH Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Tabernero J Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Medical Oncology Department, IOB-Quiron, UVic-UCC, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    مصطلحات موضوعية: Càncer - Tractament, Avaluació de resultats (Assistència sanitària), Farmacocinètica, DISEASES::Neoplasms, Other subheadings::Other subheadings::Other subheadings::/drug therapy, PHENOMENA AND PROCESSES::Physiological Phenomena::Pharmacological and Toxicological Phenomena::Pharmacological Phenomena::Dose-Response Relationship, Drug, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome, ENFERMEDADES::neoplasias, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, FENÓMENOS Y PROCESOS::fenómenos fisiológicos::fenómenos farmacológicos y toxicológicos::fenómenos farmacológicos::relación dosis-respuesta de medicamentos, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento

    وصف الملف: application/pdf

    العلاقة: Annals of Oncology;33(4); https://doi.org/10.1016/j.annonc.2021.12.012Test; Gazzah A, Bedard PL, Hierro C, Kang YK, Abdul Razak A, Ryu MH, et al. Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody–drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study. Ann Oncol. 2022 Apr;33(4):416–25.; https://hdl.handle.net/11351/8032Test; 000820214100008

    الإتاحة: https://doi.org/10.1016/j.annonc.2021.12.012Test
    https://hdl.handle.net/11351/8032Test

    View record in BASE النص الكامل

    أضف إلى المفضلة
  2. 2
    دورية أكاديمية
    Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial

    المؤلفون: Fuchs, C.S., Özgüroğlu, M., Bang, Y.-J., Di, Bartolomeo, M., Mandala, M., Ryu, M.-H., Fornaro, L.

    مصطلحات موضوعية: Chemotherapy, Gastric cancer, Gastroesophageal junction cancer, Pembrolizumab, paclitaxel, antineoplastic agent, monoclonal antibody, programmed death 1 ligand 1, adrenal insufficiency, adult, aged, alopecia, anemia, Article, colitis, controlled study, decreased appetite, diarrhea, drug response, fatigue, female, follow up, hepatitis, human, hyperthyroidism, hypophysitis, hypothyroidism, infusion related reaction, insulin dependent diabetes mellitus, major clinical study

    العلاقة: Gastric Cancer; Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı; https://doi.org/10.1007/s10120-021-01227-zTest; https://hdl.handle.net/20.500.12831/17567Test; 25; 197; 206; 2-s2.0-85114044149

    الإتاحة: https://doi.org/10.1007/s10120-021-01227-zTest
    https://doi.org/20.500.12831/17567Test
    https://hdl.handle.net/20.500.12831/17567Test

    View record in BASE النص الكامل

    أضف إلى المفضلة
  3. 3
    دورية أكاديمية
    Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100

    المؤلفون: Moehler, M, Dvorkin, M, Boku, N, Ozguroglu, M, Ryu, M-H, Muntean, AS, Lonardi, S, Nechaeva, M, Bragagnoli, AC, Coskun, HS, Cubillo Gracian, A, Takano, T, Wong, R, Safran, H, Vaccaro, GM, Wainberg, ZA, Silver, MR, Xiong, H, Hong, J, Taieb, J, Bang, Y-J

    العلاقة: Moehler, M., Dvorkin, M., Boku, N., Ozguroglu, M., Ryu, M. -H., Muntean, A. S., Lonardi, S., Nechaeva, M., Bragagnoli, A. C., Coskun, H. S., Cubillo Gracian, A., Takano, T., Wong, R., Safran, H., Vaccaro, G. M., Wainberg, Z. A., Silver, M. R., Xiong, H., Hong, J. ,. Bang, Y. -J. (2021). Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100. JOURNAL OF CLINICAL ONCOLOGY, 39 (9), https://doi.org/10.1200/JCO.20.00892Test.; http://hdl.handle.net/11343/304515Test

    الإتاحة: https://doi.org/10.1200/JCO.20.00892Test
    http://hdl.handle.net/11343/304515Test

    View record in BASE

    أضف إلى المفضلة
  4. 4
    دورية أكاديمية
    Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma

    المؤلفون: Shitara, K., Ozguroglu, M., Bang, Y-J, Di Bartolomeo, M., Mandala, M., Ryu, M-H, Caglevic, C., Chung, H. C., Muro, K., Van Cutsem, E., Kobie, J., Cristescu, R., Aurora-Garg, D., Lu, J., Shih, C-S, Adelberg, D., Cao, Z. A., Fuchs, C. S.

    المساهمون: 방영주, Bang, Y-J

    مصطلحات موضوعية: TUMOR MUTATIONAL BURDEN, CTLA-4 BLOCKADE, PD-1 BLOCKADE, BENEFIT, CHEMO, pembrolizumab, chemotherapy, gastroesophageal adenocarcinoma, gastric cancer

    العلاقة: Annals of Oncology, Vol.32 No.9, pp.1127-1136; 141544; https://hdl.handle.net/10371/178109Test; 000687824100008; 2-s2.0-85109047875

    الإتاحة: https://doi.org/10.1016/j.annonc.2021.05.803Test
    https://hdl.handle.net/10371/178109Test

    View record in BASE النص الكامل

    أضف إلى المفضلة
  5. 5
    دورية أكاديمية
    Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group

    المؤلفون: Park, S. H., Ryu, M. H., Ryoo, B. Y., Im, S. A., Kwon, H. C., Lee, S. S., Park, S. R., Kang, B. Y., Kang, Y. K.

    المساهمون: 임석아, Im, S. A.

    مصطلحات موضوعية: IMATINIB MESYLATE, DOSE IMATINIB, PROGRESSION, RESISTANCE, KIT, BAY-43-9006, GUIDELINE, NILOTINIB, THERAPY, TRIAL, Sorafenib, Gastrointestinal stromal tumor

    العلاقة: Investigational New Drugs, Vol.30 No.6, pp.2377-2383; 146790; https://hdl.handle.net/10371/177205Test; 000310470100030; 2-s2.0-84864408861

    الإتاحة: https://doi.org/10.1007/s10637-012-9795-9Test
    https://hdl.handle.net/10371/177205Test

    View record in BASE النص الكامل

    أضف إلى المفضلة
  6. 6
    دورية أكاديمية
    Simulation and validation for count-based binary decision of target blood pressure achievement in home blood pressure monitoring data analysis for clinical practice

    المؤلفون: Lee, Y, Shin, J, Shin, J H, Kim, H J, Ryu, M H, Park, H C, Lim, H Y, Park, J K, Heo, R, Kim, W H

    المصدر: European Heart Journal ; volume 42, issue Supplement_1 ; ISSN 0195-668X 1522-9645

    مصطلحات موضوعية: Cardiology and Cardiovascular Medicine

    الإتاحة: https://doi.org/10.1093/eurheartj/ehab724.2351Test
    https://academic.oup.com/eurheartj/article-pdf/42/Supplement_1/ehab724.2351/41058528/ehab724.2351.pdfTest

    View record in BASE

    أضف إلى المفضلة
  7. 7
    دورية أكاديمية
    521P Dose escalation study of two different alternative dosing schedules of tusamitamab ravtansine (tusa, SAR408701) in patients (pts) with advanced solid tumors

    المؤلفون: Tabernero, J., Bedard, P., Bang, Y-J., Vieito, M., Ryu, M-H., Fagniez, N., Yoruk, S., Charbonnier, L., Soufflet, C., Masson, N., Gazzah, A.

    المساهمون: Meso Scale Diagnostics, AstraZeneca, Novartis, Amgen, Sanofi

    المصدر: Annals of Oncology ; volume 32, page S589-S590 ; ISSN 0923-7534

    مصطلحات موضوعية: Oncology, Hematology

    الإتاحة: https://doi.org/10.1016/j.annonc.2021.08.1043Test
    https://api.elsevier.com/content/article/PII:S0923753421032725?httpAccept=text/xmlTest
    https://api.elsevier.com/content/article/PII:S0923753421032725?httpAccept=text/plainTest

    View record in BASE

    أضف إلى المفضلة
  8. 8
    دورية أكاديمية
    Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: Exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial

    المؤلفون: Shitara K., Di Bartolomeo M., Mandala' M., Ryu M. -H., Caglevic C., Olesinski T., Chung H. C., Muro K., Goekkurt E., McDermott R. S., Mansoor W., Wainberg Z. A., Shih C. -S., Kobie J., Nebozhyn M., Cristescu R., Cao Z. A., Loboda A., Ozgurolu M.

    المساهمون: Shitara, K., Di Bartolomeo, M., Mandala', M., Ryu, M. -H., Caglevic, C., Olesinski, T., Chung, H. C., Muro, K., Goekkurt, E., Mcdermott, R. S., Mansoor, W., Wainberg, Z. A., Shih, C. -S., Kobie, J., Nebozhyn, M., Cristescu, R., Cao, Z. A., Loboda, A., Ozgurolu, M.

    مصطلحات موضوعية: Gastrointestinal Neoplasms, Gene Expression Profiling, Genetic Markers, Immunotherapy, Programmed Cell Death 1 Receptor

    العلاقة: info:eu-repo/semantics/altIdentifier/pmid/37399357; info:eu-repo/semantics/altIdentifier/wos/WOS:001033548200010; volume:11; issue:6; journal:JOURNAL FOR IMMUNOTHERAPY OF CANCER; https://hdl.handle.net/11391/1566839Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85164007633

    الإتاحة: https://doi.org/10.1136/jitc-2023-006920Test
    https://hdl.handle.net/11391/1566839Test

    View record in BASE

    أضف إلى المفضلة
  9. 9
    دورية أكاديمية
    1422MO Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-low, advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Results of the exploratory cohorts in the phase II, multicenter, open-label DESTINY-Gastric01 study

    المؤلفون: Yamaguchi, K., Bang, Y-J., Iwasa, S., Sugimoto, N., Ryu, M-H., Sakai, D., Chung, H.C., Kawakami, H., Yabusaki, H., Lee, J., Saito, K., Kawaguchi, Y., Kamio, T., Kojima, A., Sugihara, M., Shitara, K.

    المصدر: Annals of Oncology ; volume 31, page S899-S900 ; ISSN 0923-7534

    مصطلحات موضوعية: Oncology, Hematology

    الإتاحة: https://doi.org/10.1016/j.annonc.2020.08.1928Test
    https://api.elsevier.com/content/article/PII:S0923753420419246?httpAccept=text/xmlTest
    https://api.elsevier.com/content/article/PII:S0923753420419246?httpAccept=text/plainTest

    View record in BASE

    أضف إلى المفضلة
  10. 10
    دورية أكاديمية
    Phase III randomized study of neoadjuvant chemotherapy (CT) with docetaxel(D), oxaliplatin(O) and S-1(S) (DOS) followed by surgery and adjuvant S-1, vs surgery and adjuvant S-1, for resectable advanced gastric cancer (GC) (PRODIGY)

    المؤلفون: Kang, Y.-K., Yook, J.H., Park, Y.-K., Kim, Y.-W., Kim, J., Ryu, M.-H., Rha, S.Y., Chung, I.-J., Kim, I.-H., Oh, S.C., Yoo, C.-H., Choi, J.-H., Zang, D.Y., Kim, G., Lee, Y., Noh, S.-H.

    المصدر: Annals of Oncology ; volume 30, page v876-v877 ; ISSN 0923-7534

    مصطلحات موضوعية: Oncology, Hematology

    الإتاحة: https://doi.org/10.1093/annonc/mdz394.032Test
    https://api.elsevier.com/content/article/PII:S0923753419603923?httpAccept=text/xmlTest
    https://api.elsevier.com/content/article/PII:S0923753419603923?httpAccept=text/plainTest
    http://academic.oup.com/annonc/article-pdf/30/Supplement_5/mdz394.032/30082726/mdz394.032.pdfTest

    View record in BASE

    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS — أرسل هذا البحث بالبريد الإلكتروني — حفظ البحث